17 Feb 2026 | 5 Mins Read
Fortis Healthcare gets bullish calls; up to 25% upside seen
Flipitmoney
Analysts at UBS, Citi, and JPMorgan are positive on Fortis Healthcare Ltd. with 'buy' or 'overweight' ratings and target prices of ₹1,150 to ₹1,120 per share, indicating up to 25% upside potential. The company reported a healthy third quarter with 17.5% revenue growth and 35% EBITDA increase, supported by growth catalysts including hospital expansion and IHH equity infusion.